MRP Capital Investments LLC Buys Shares of 5,000 Elanco Animal Health Incorporated (NYSE:ELAN)

MRP Capital Investments LLC purchased a new stake in Elanco Animal Health Incorporated (NYSE:ELAN) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 5,000 shares of the company’s stock, valued at approximately $61,000.

Several other institutional investors and hedge funds have also bought and sold shares of ELAN. Victory Capital Management Inc. raised its holdings in Elanco Animal Health by 10.2% during the third quarter. Victory Capital Management Inc. now owns 102,414 shares of the company’s stock worth $1,504,000 after acquiring an additional 9,480 shares in the last quarter. Quest Partners LLC raised its stake in Elanco Animal Health by 915.1% in the third quarter. Quest Partners LLC now owns 16,201 shares of the company’s stock valued at $238,000 after buying an additional 14,605 shares during the period. Pathstone Holdings LLC raised its stake in Elanco Animal Health by 0.7% in the third quarter. Pathstone Holdings LLC now owns 546,793 shares of the company’s stock valued at $8,032,000 after buying an additional 3,698 shares during the period. B. Metzler seel. Sohn & Co. Holding AG bought a new stake in Elanco Animal Health in the third quarter valued at approximately $572,000. Finally, Commerce Bank raised its stake in Elanco Animal Health by 2.2% in the third quarter. Commerce Bank now owns 35,114 shares of the company’s stock valued at $516,000 after buying an additional 741 shares during the period. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Trading Down 2.2 %

Shares of ELAN stock opened at $10.60 on Friday. The stock’s fifty day moving average price is $11.38 and its two-hundred day moving average price is $12.64. The company has a market cap of $5.24 billion, a PE ratio of 26.49, a P/E/G ratio of 2.50 and a beta of 1.44. Elanco Animal Health Incorporated has a fifty-two week low of $10.03 and a fifty-two week high of $18.80. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01). Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter in the previous year, the company posted $0.08 earnings per share. The firm’s revenue was down 1.4% on a year-over-year basis. Equities analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Lawrence Erik Kurzius bought 10,000 shares of the stock in a transaction that occurred on Tuesday, March 11th. The stock was acquired at an average cost of $10.20 per share, with a total value of $102,000.00. Following the transaction, the director now directly owns 111,459 shares in the company, valued at approximately $1,136,881.80. This trade represents a 9.86 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.57% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have issued reports on ELAN. UBS Group dropped their price objective on Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating on the stock in a research note on Wednesday, February 26th. Leerink Partnrs raised Elanco Animal Health to a “hold” rating in a research report on Monday, December 2nd. Stifel Nicolaus decreased their target price on Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating on the stock in a research report on Friday, February 21st. Piper Sandler decreased their target price on Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating on the stock in a research report on Thursday, March 6th. Finally, Leerink Partners assumed coverage on Elanco Animal Health in a research report on Monday, December 2nd. They set a “market perform” rating and a $14.00 price target on the stock. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $15.17.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.